Dear Editor,

Uridine diphosphate-glucuronosyltransferase 1A (UGT1A1), an enzyme encoded by the *UGT1A1* gene on chromosome 2q37, is the major bilirubin-conjugating enzyme \[[@B1][@B2]\]. Variants in the promoter and coding regions of *UGT1A1* affect the enzyme activity of UGT1A1, leading to unconjugated hyperbilirubinemia disorders, including Gilbert syndrome (GS), Crigler-Najjar syndrome type I (CNI), and Crigler-Najjar syndrome type II (CNII). Variant frequencies show inter-ethnic differences \[[@B3][@B4]\]. Reports on the spectrum of variants in Korean patients with hyperbilirubinemia are limited thus far; they are mostly based on a small number of patients evaluating a few mutational hotspots \[[@B5][@B6]\]. We retrospectively investigated the spectrum of *UGT1A1* variation in a larger study population to examine the allele distribution in Korean patients with unconjugated hyperbilirubinemia.

We collected clinical data of 81 patients with hyperbilirubinemia who underwent *UGT1A1* genotyping between April 2013 and March 2019 in Gangnam Severance Hospital, Seoul, Korea. For comparison, we retrieved allele frequencies of 1,722 Korean subjects from the Korean Reference Genome database (KRGDB, <http://coda.nih.go.kr/coda/KRGDB/index.jsp>), and of 80 Chinese and 71 Japanese healthy subjects from published data \[[@B7][@B8]\]. For association analysis of genotypes and total bilirubin (TB) levels, we retrieved allele frequencies and laboratory data from a published study \[[@B9]\]. This study was approved by the Institutional Review Board of Yonsei University Health System, Gangnam Severance Hospital (IRB-2019-0188-001). The need for informed consent of the participants for reviewing medical records was waived on the condition that the research involves no more than minimal risk to the patients and the patient\'s privacy was thoroughly protected.

The promoter region, including the TATA box and all five exons with flanking introns of *UGT1A1*, were PCR-amplified in a 3500 Dx Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) using an in-house method. The sequences were compared with a *UGT1A1* reference sequence (accession number: NM_000463.2) registered in the National Center for Biotechnology Information database (<https://www.ncbi.nlm.nih.gov>). Two independent experts evaluated the variants, and the haplotype was annotated according to *UGT1A1* allele nomenclature guidelines (<https://www.pharmacogenomics.pha.ulaval.ca/wp-content/uploads/2015/04/UGT1A1-allele-nomenclature.html>).

Statistical analyses were conducted using Analyse-it v.5.11 Method Evaluation edition (Analyse-it Software, Ltd., Leeds, UK). Allele frequencies in the control and study groups were compared using Fisher\'s exact test. Results were considered significant at *P*\<0.05.

We detected nine variants in this study ([Table 1](#T1){ref-type="table"}). All variants identified in exons were missense variants, and two novel variants (c.864+2T\>C and p.Ala61Gly) were detected. The most frequent allele was *UGT1A1*\*28, with a frequency of 43.8% (71/162), followed by the *UGT1A1*\*6 allele, with a frequency of 31.5% (51/162). The frequency of the wild-type allele was 4.9% (8/162) in the 81 hyperbilirubinemia patients. The frequencies of the *UGT1A1*\*28, *UGT1A1*\*6, *UGT1A1*\*27, and *UGT1A1*\*7 alleles were significantly different between patients and the Korean control group.

[Table 2](#T2){ref-type="table"} shows the *UGT1A1* genotypes detected in 46 patients with available clinical data. Homozygous *UGT1A1*\*7 alleles with homozygous or heterozygous *UGT1A1*\*6 alleles were detected in two CNII patients only, and these patients showed the highest TB levels (79.87 µmol/L and 75.24 µmol/L, respectively). Forty-three GS patients were grouped into 10 different *UGT1A1* genotypes. Heterozygous or homozygous *UGT1A1*\*28 (TA6/7, TA7/7) (58.1%, 50/86) and heterozygous or homozygous *UGT1A1*\*6 (30.2%, 26/86) were frequently identified in GS patients.

In this study, *UGT1A1*\*28 and *UGT1A1*\*6 were the most frequent alleles. While *UGT1A1*\*6 is the most frequent allele in East Asian hyperbilirubinemia patients \[[@B3]\], *UGT1A1*\*28 was the most frequent allele (44.3%, 51/81) in this study. Two CNII patients were homozygous for the *UGT1A1*\*7 allele in combination with the *UGT1A1*\*6 allele. Homozygous genotype of the *UGT1A1*\*7 allele has been previously reported in CNII cases \[[@B5][@B6][@B7][@B8]\]. Homozygous *UGT1A1*\*7 allele has a strong association with CNII in the Asian population \[[@B6]\], in line with our results.

Two patients carried novel variants. A 57-year-old female patient had a c.864+2T\>C variant combined with a heterozygous *UGT1A1*\*28 allele. c.864+2T\>C is a variant at the splice-donor site at the 5′ end of intron 1. An adjacent splice-donor site variant, c.864+1G\>C, has been reported in a CNI patient in a homozygous genotype, and this variant is expected to induce splicing at a cryptic site \[[@B10]\]. Therefore, we believe that the c.864+2T\>C variant contributed to the medical condition of the patient. A five-year-old male patient had a c.182C\>G variant combined with compound heterozygous *UGT1A1*\*6 and *UGT1A1*\*28 alleles. c.182C\>G is a missense variant in exon 1. Further evidence based on more patient cases and investigation of the effects of these variants on enzyme activity are needed to assign a pathogenic role to these two novel variants; we interpreted these variants as variant of uncertain significance according to American College of Medical Genetics guidelines \[[@B11]\].

In conclusion, from the spectrum of *UGT1A1* variations, *UGT1A1*\* 28 and \*6 alleles tend to be prevalent in Korean patients with unconjugated hyperbilirubinemia and the *UGT1A1*\*28 allele tends to be more prevalent than in other Asian populations.
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###### Variants and frequencies of *UGT1A1* detected in patients with hyperbilirubinemia (N=81) and healthy controls

![](alm-40-281-i001)

  Location   Nucleotide change   Marker allele   Predicted amino acid change   Minor allele frequency (number of heterozygotes/homozygotes)   *P*^†^         dbSNP                                  
  ---------- ------------------- --------------- ----------------------------- -------------------------------------------------------------- -------------- -------------- ------- --------------- --------------
  Promoter   c.-64G \> C         ^\*^81          \-                            0.037 (6/0)                                                    \-             \-             0.036   0.832           rs873478
  Promoter   c.-41\_-40dupTA     ^\*^28          \-                            0.438 (31/20)                                                  0.144 (21/1)   0.113 (12/2)   0.200   **\< 0.0001**   rs34983651
  Intron 1   c.864+2T \> C       Novel           \-                            0.006 (1/0)                                                    \-             \-             0.000   **0.045**       rs772088902
  Exon 1     c.182C \> G         Novel           p.Ala61Gly                    0.006 (1/0)                                                    \-             \-             0.000   **0.045**       rs1273237448
  Exon 1     c.211G \> A         ^\*^6           p.Gly71Arg                    0.315 (31/10)                                                  0.169 (23/2)   0.183 (20/3)   0.173   **\< 0.0001**   rs4148323
  Exon 1     c.686C \> A         ^\*^27          p.Pro229Gln                   0.037 (6/0)                                                    0.013 (2/0)    \-             0.014   **0.030**       rs35350960
  Exon 4     c.1091C \> T        ^\*^73          p.Pro364Leu                   0.031 (5/0)                                                    0.006 (1/0)    \-             0.013   0.077           rs34946978
  Exon 5     c.1456T \> G        ^\*^7           p.Tyr486Asp                   0.031 (1/2)                                                    0.000 (0/0)    0.014 (2/0)    0.001   **\< 0.0001**   rs34993780
  Exon 5     c.1352C \> T        N/A             p.Pro451Leu                   0.006 (1/0)                                                    \-             \-             0.001   0.241           rs114982090

Values in bold indicate statistical significance.

^\*^Korean Reference Genome database (<http://coda.nih.go.kr/coda/KRGDB/index.jsp>); ^†^P values for comparison between Korean patients with hyperbilirubinemia and Korean control subjects were calculated based on Fisher\'s exact test.

###### Genotyping of *UGT1A1* in hyperbilirubinemia patients with clinical data (N=46)
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  Genotype   Promoter TATA box   Coding region                         Patients (N = 46)   Controls \[[@B9]\] (N = 324)         
  ---------- ------------------- ------------------------------------- ------------------- ------------------------------ ----- --------------
  1          Wild                Wild                                  HS (1)              69.08                          148   13.34 ± 3.42
  2          TA6/7               p.Gly71Arg +/− ; p.Ala61Gly +/−       GS (1)              20.52                          \-    \-
  3          Wild                p.Gly71Arg +/+                        GS (3)              25.65 ± 2.91                   18    23.60 ± 6.16
  4          TA6/7               p.Pro229Gln +/−                       GS (2)              28.22 ± 1.20                   \-    \-
  5          TA7/7               p.Pro229Gln +/+                       GS (1)              30.78                          \-    \-
  6          TA6/7               Wild                                  GS (3)              34.54 ± 15.56                  49    17.27 ± 5.64
  7          TA7/7               p.Pro364Leu +/--                      GS (2)              35.91 ± 7.18                   \-    \-
  8          Wild                p.Gly71Arg +/--                       GS (4)              34.71 ± 12.31                  83    15.90 ± 3.25
  9          TA6/7               p.Gly71Arg +/--                       GS (14)             40.01 ± 24.45                  19    24.62 ± 5.13
  10         TA7/7               Wild                                  GS (12)             46.68 ± 17.10                  7     33.17 ± 4.10
  11         Wild                p.Gly71Arg +/-- ; p. Pro364Leu +/--   GS (1)              61.56                          \-    \-
  12         Wild                p.Gly71Arg +/-- ; p.Tyr486Asp +/+     CNII (1)            75.24                          \-    \-
  13         Wild                p.Gly71Arg +/+ ; p.Tyr486Asp +/+      CNII (1)            79.86                          \-    \-

Abbreviations: +/−, heterozygous variant; +/+, homozygous variant; GS, Gilbert\'s syndrome; CNII, Crigler-Najjar syndrome II; HS, hereditary spherocytosis; TB, total bilirubin.
